Key result
Dapagliflozin improves glycemic control and yields dual cardiovascular and renal benefits in high-risk T2D.
Why the study?
Does dapagliflozin improve safety, glycemic control, cardiovascular health, and renal outcomes in patients with diabetic nephropathy and cardiovascular risk?
Does dapagliflozin improve safety, glycemic control, cardiovascular health, and renal outcomes in patients with diabetic nephropathy and cardiovascular risk?
This review highlights dapagliflozin as a safe and effective therapy for improving glycemic, cardiovascular, and renal outcomes in patients with diabetic nephropathy and cardiovascular risk.
INTRODUCTION: Diabetic nephropathy is a significant concern for patients with cardiovascular disease. Dapagliflozin, an SGLT2 inhibitor, has emerged as a promising therapeutic approach to managing diabetic nephropathy and reducing cardiovascular risk. AREAS COVERED: This review encompasses the research and literature search methodology, including clinical trials and real-world evidence, assessing the safety profile of Dapagliflozin in patients with diabetic nephropathy and cardiovascular risk. EXPERT OPINION: Dapagliflozin, an SGLT2 inhibitor, has redefined patient-centric care by simultaneously improving glycemic control, cardiovascular health, and renal outcomes in individuals with type 2 diabetes, cardiovascular disease, and nephropathy.
No takes yet. Share an insight, caveat, or question.
Sood et al. (2025) conducted a review in Diabetic nephropathy and cardiovascular risk. Dapagliflozin was evaluated. Dapagliflozin improves glycemic control, cardiovascular health, and renal outcomes in individuals with type 2 diabetes, cardiovascular disease, and nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: